Molin Y, Gallay C, Gautier J, Lardy-Cleaud A, Mayet R, Grach M et al (2019) PALLIA -10, a screening tool to identify patients needing palliative care referral in comprehensive cancer centers: A prospective multicentric study (PREPA -10). Cancer Med 8(6):2950–2961

Barbot AC, Mussault P, Ingrand P, Tourani JM (2008) Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors. J Clin Oncol 26(15):2538–2543

Article  PubMed  Google Scholar 

Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the karnofsky performance status. Cancer 45(8):2220–2224

Article  CAS  PubMed  Google Scholar 

Esposito M, Ganesan S, Kang Y (2021) Emerging strategies for treating metastasis. Nat Cancer 2(3):258–270

Article  PubMed  PubMed Central  Google Scholar 

Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, Diéras V et al (2021) Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort. ESMO Open 6(3):100114

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gulati S, Labaki C, Karachaliou GS, Choueiri TK, Zhang T (2022) First-line treatments for metastatic clear cell renal cell carcinoma: an ever-enlarging landscape. Oncologist 27(2):125–134

Article  PubMed  PubMed Central  Google Scholar 

Bouleuc C, Chvetzoff G. (2018) Chimiothérapie et cancer en phase palliative avancée. Référence AFSOS, update 3–18, Référentiels Inter-Régionaux en Soins Oncologiques de Support [Internet]. Available from: https://www.afsos.org/wp-content/uploads/2014/12/Chimioth%C3%A9rapie-et-cancer_phase-palliative-avanc%C3%A9e_AFSOS.pdf. Accessed 29 Jan 2024.

Brom L, De Snoo-Trimp JC, Onwuteaka-Philipsen BD, Widdershoven GAM, Stiggelbout AM, Pasman HRW (2017) Challenges in shared decision making in advanced cancer care: a qualitative longitudinal observational and interview study. Health Expect 20(1):69–84

Article  PubMed  Google Scholar 

Wasp GT, Knutzen KE, Murray GF, Brody-Bizar OC, Liu MA, Pollak KI et al (2021) Systemic therapy decision making in advanced cancer: a qualitative analysis of patient-oncologist encounters. JCO Oncology Practice 18(8):e1357

Article  PubMed  PubMed Central  Google Scholar 

Bourgeois H, Grudé F, Solal-Céligny P, Dupuis O, Voog E, Ganem G et al (2017) Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study. Ann Oncol 28(7):1612‑7

McMillan DC (2013) The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 39(5):534–540

Article  PubMed  Google Scholar 

Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P et al (2017) Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev 58:1–13

Article  PubMed  Google Scholar 

Bagni K, Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Hansen CP et al (2020) Prognostic impact of Charlson’s age-comorbidity index and other risk factors in patients with pancreatic cancer. Eur J Cancer Care (Engl) 29(3):e13219

Article  PubMed  Google Scholar 

Chen L, Qi Y, Kong X, Su Z, Wang Z, Wang X et al (2022) Nutritional risk index predicts survival in patients with breast cancer treated with neoadjuvant chemotherapy. Frontiers in Nutrition 8:786742

Article  PubMed  PubMed Central  Google Scholar 

Moroni M, Zocchi D, Bolognesi D, Abernethy A, Rondelli R, Savorani G et al (2014) The « surprise » question in advanced cancer patients: a prospective study among general practitioners. Palliat Med 28(7):959–964

Article  PubMed  Google Scholar 

Moss AH, Lunney JR, Culp S, Auber M, Kurian S, Rogers J et al (2010) Prognostic significance of the « surprise » question in cancer patients. J Palliat Med 13(7):837–840

Article  PubMed  Google Scholar 

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A et al (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology 32(12):1475–1495

Article  CAS  PubMed  Google Scholar 

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N et al (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for clinical actionability of molecular Targets (ESCAT). Annals of Oncology 29(9):1895–1902

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hempel L, de Oliveira JV, Gaumann A, Milani V, Schweneker K, Schenck K et al (2021) Landscape of biomarkers and actionable gene alterations in adenocarcinoma of GEJ and Stomach-A Real World Data Analysis. Cancers (Basel) 13(17):4453

Article  CAS  PubMed  Google Scholar 

Voutsadakis IA (2014) The chemosensitivity of testicular germ cell tumors. Cell Oncol (Dordr) 37(2):79–94

Article  CAS  PubMed  Google Scholar 

Das S, Al-Toubah T, Strosberg J (2021) Chemotherapy in neuroendocrine tumors. Cancers (Basel) 13(19):4872

Article  CAS  PubMed  Google Scholar 

Kemp Z, Ledermann JA (2013) Update on first-line treatment of advanced ovarian carcinoma. International Journal of Women’s Health 5:45

CAS  PubMed  PubMed Central  Google Scholar 

Mattiuzzi C, Lippi G (2019) Current cancer epidemiology. J Epidemiol Glob Health 9(4):217–222

Article  PubMed  PubMed Central  Google Scholar 

Lena H, Monnet I, Bylicki O, Audigier-Valette C, Falchero L, Vergnenegre A et al (2022) Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06–2015 study). JCO 40(16_suppl):9011‑9011

Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B et al (2023) First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet 402(10400):451–463

Article  CAS  PubMed  Google Scholar 

West H (Jack) (2015) Immune Checkpoint Inhibitors. JAMA Oncolo 1(1):115

Ramnaraign BH, Chatzkel JA, Al-Mansour ZA, Rogers S, Jones D, DeRemer D et al (2021) Immunotherapy management in special cancer patient populations. JCO Oncology Practice 17(5):240–245

Article  PubMed  Google Scholar 

Patel AK, Duperreault MF, Pandya CJ et al (2023) Outcomes of immune checkpoint inhibitor administration in hospitalized patients with solid tumor malignancies. JCO Oncol Pract 19(2):e298–e305. https://doi.org/10.1200/OP.22.00256

Wang F, Wang S, Zhou Q (2020) The resistance mechanisms of lung cancer immunotherapy. Front Oncol 10:568059

Article  PubMed  PubMed Central  Google Scholar 

Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J et al (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327(7408):195–198

Article  PubMed  PubMed Central  Google Scholar 

Baszanger I (2012) One more chemo or one too many? Defining the limits of treatment and innovation in medical oncology. Social Science and Medicine 75(5):864–872

Article  PubMed  Google Scholar 

Helft PR (2005) Necessary collusion: prognostic communication with advanced cancer patients. J Clin Oncol 23(13):3146–50

Article  PubMed  Google Scholar 

Kaasa S, Loge JH, Aapro M, Albreht T, Anderson R, Bruera E et al (2018) Integration of oncology and palliative care: a lancet oncology commission. Lancet Oncol 19(11):e588-653

Article  PubMed  Google Scholar